This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Wildon Farwell Biography and Net Worth

Insider of Dyne Therapeutics

Dr. Farwell joins Dyne from Biogen, Inc., where he was vice president, global head of neuromuscular diseases, medical affairs. During his 10 years at Biogen, Dr. Farwell led the development and life cycle management of SPINRAZA® (nusinersen), an oligonucleotide and the first therapy approved for the treatment of spinal muscular atrophy. He also led the late-stage development of tofersen, an investigational oligonucleotide therapy for amyotrophic lateral sclerosis, oversaw clinical and biomarker development for Biogen’s neuromuscular disease portfolio, and began his tenure at the company leading pharmacovigilance for multiple product candidates. Previously, Dr. Farwell was an Assistant Professor in Medicine at Harvard Medical School and a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He received his M.D. from the University of Missouri School of Medicine and an MPH in clinical effectiveness from Harvard University School of Public Health.

What is Wildon Farwell's net worth?: The estimated net worth of Wildon Farwell is at least $3.64 million as of March 11th, 2024. Dr. Farwell owns 151,590 shares of Dyne Therapeutics stock worth more than $3,636,644 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Farwell may own. Learn More about Wildon Farwell's net worth.
How do I contact Wildon Farwell?: The corporate mailing address for Dr. Farwell and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Wildon Farwell's contact information.
Has Wildon Farwell been buying or selling shares of Dyne Therapeutics?: Wildon Farwell has not been actively trading shares of Dyne Therapeutics in the last ninety days. Most recently, Wildon Farwell sold 1,585 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a transaction totalling $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares of the company's stock, valued at $3,895,863. Learn More on Wildon Farwell's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Susanna High (COO), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 1,746,285 shares worth more than $31,057,267.50. During the last year, insiders at the sold shares 48 times. They sold a total of 2,547,573 shares worth more than $62,638,020.82. The most recent insider tranaction occured on December, 11th when insider Oxana Beskrovnaya sold 2,334 shares worth more than $65,632.08. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 12/11/2024.

Wildon Farwell Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	1,585	$25.70	$40,734.50	151,590
2/12/2024	Sell	5,493	$25.07	$137,709.51	163,503
1/26/2024	Sell	100	$25.00	$2,500.00	168,996
9/12/2023	Sell	1,707	$10.41	$17,769.87	89,250
3/2/2022	Sell	5,617	$8.56	$48,081.52

Wildon Farwell Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $23.99

$23.65

$24.90

50 Day Range

MA: $29.63

$23.99

$35.40

2 Week Range

Now: $23.99

$11.93

$47.45

Volume

1,456,217 shs

Average Volume

1,437,825 shs

Market Capitalization

$2.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad